low-dose naltrexone

Pyridostigmine and low-dose naltrexone for ME/CFS: study protocol for the Life Improvement Trial (LIFT), a randomized, double-blind, placebo-controlled clinical trial Meadows, Danielle; Squires, Johanna; Dibble, Joshua; Palwayi, Shreya; Felsenstein, Donna; Tannenbaum, Linda; Li, Peng; Xiao...

Low Dose Naltrexone for Post-COVID Fatigue Syndrome: A Randomized Controlled Trial OBJECTIVES To assess the efficacy and safety of low-dose naltrexone (LDN) for reducing fatigue severity at 16 weeks in persons with post-COVID fatigue syndrome (PCFS). DESIGN Decentralized, randomized, parallel...

Symptom Response to Low-Dose Naltrexone in Fibromyalgia: An Exploratory Analysis of the Randomized Placebo-Controlled FINAL Trial Nielsen, Maria Juul; Vaegter, Henrik Bjarke; Bruun, Karin Due Abstract Background: Fibromyalgia (FM) remains difficult to manage due to a highly variable symptom...

Poster abstract from the EULAR rheumatology conference - EFFICACY OF LOW-DOSE NALTREXONE FOR FIBROMYALGIA: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL WITH 12 MONTHS OF FOLLOW-UP (Luciano et al., 2026) Low-Dose Naltrexone Fails to Outperform Placebo for Pain in Fibromyalgia Treatment...

The expanding potential of low-dose naltrexone in clinical practice with a focus on long COVID Practice Points 1. Use of low-dose naltrexone, typically dosed between 3 and 5 mg, is increasing in clinical practice for indications such as fibromyalgia, chronic pain syndrome, and post-COVID...

https://link.springer.com/article/10.1007/s12325-026-03612-5 Low-Dose Naltrexone: What is the Evidence? A Narrative Review Review Open access Published: 30 April 2026 (2026) Cite this article You have full access to thisopen accessarticle Download PDF Save article Advances in TherapyAims and...

NCNED Facebook page: https://www.facebook.com/share/1D19rhrpH5/?mibextid=wwXIfr / NCNED is launching its first Double Blind 12 week Clinical Trial to investigate the effects of low dose naltrexone (LDN) in individuals with ME/CFS commencing in late March 2026. We are currently...

Preprint. See post #3 for published version. Effect of low dose naltrexone for long covid: a systematic review Oyungerel Byambasuren, Tiffany J Atkins, Shaira Baptista, Paul Glasziou, Samantha Chakraborty [Line breaks added] Background Long covid is a debilitating chronic condition, and the...

Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) https://www.tandfonline.com/doi/full/10.1080/21641846.2019.1692770 Olli Polo, Pia Pesonen & Essi Tuominen ABSTRACT Background: Myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) is...

Thought we should have a thread for this trial as it is often cited as evidence of efficacy of LDN in fibromyalgia. Randomized Controlled Trial Arthritis Rheum. 2013 Feb;65(2):529-38. doi: 10.1002/art.37734. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small...

Low-Dose Naltrexone for Severe Fibromyalgia Syndrome: A Report of a Case With Two-Year Follow-Up Ulrich Moser [Line breaks added] Abstract Fibromyalgia syndrome (FMS) is characterized by diffuse musculoskeletal pain associated with daytime fatigue, sleep disturbance, cognitive deficits, and...

Abstract Low-dose naltrexone (LDN) has demonstrated mixed efficacy in treating fibromyalgia. This systematic review and meta-analysis aimed to evaluate the efficacy of LDN for fibromyalgia. We systematically searched electronic databases and gray literature from inception to May 2024. Included...

Hi, I am curious as to whether anyone has some developed hypotheses as to the mechanism of 'low-dose' Naltrexone? Much of the discourse about Naltrexone is dominated by discussion of it being a competitive inhibitor of the function of of mu-opioid receptors. But it is known that at lower...

Abstract Introduction: Fibromyalgia (FM) is a chronic fluctuating, nociplastic pain condition. Naltrexone is a µ-opioid-receptor antagonist; preliminary studies have indicated a pain-relieving effect of low-dose naltrexone (LDN) in patients with FM. The impetus for studying LDN is the...

Clinical trial registration. There is a growing number of individuals who do not recover to previous levels of health and function following an acute infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but rather develop what has been referred to as 'Long-COVID'...

For poll results as of October 2026 (around the time when LDN trial results suggested LDN is not helpful for ME/CFS) - see post #156 The UK government working party on research strategy for ME has been discussing the value of setting up trials for drug repurposing. LDN is a contender. I would...

Full title: Potential therapeutic benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 ion channels in pathophysiology and treatment Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating...

https://casereports.bmj.com/content/13/1/e232502

Source: Solve ME/CFS Initiative Date: December 13, 2018 Time: 18:00-19:00 UTC URL: https://register.gotowebinar.com/register/1541028613190392835 ME/CFS Involves Brain Inflammation: Results from a Ramsay Pilot Study ---------------------------------------------------------- Presented by...

[I'm not impressed with the way the abstract for this study is written] https://www.tandfonline.com/doi/full/10.1080/21641846.2018.1477034 Original Articles Double-blinded placebo-controlled cross-over pilot trial of naltrexone to treat Gulf War Illness Kori L. Brewer...